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Abstract
Background: Intravitreal vascular endothelial growth factor (VEGF) inhibitors stabilize vision
in a majority of patients with neovascular age-related macular degeneration (AMD) and can
improve vision in almost 40% of patients. However, some individuals who respond to antiVEGF treatment still lose vision due to the formation of geographic atrophy (GA). While
optical coherence tomography is often the primary imaging modality used, fluorescein
angiography (FA) can provide useful information on GA development after choroidal
neovascularization (CNV) regression.
Methods: A retrospective chart review was conducted to evaluate the changes seen on FA
over a 47-month period for 3 patients with neovascular AMD treated with anti-VEGF
inhibitors.
Results: All 3 patients were initially noted to have subfoveal CNV due to AMD at baseline;
they were followed up monthly and treated on an as needed basis for at least 47 months
with intravitreal VEGF inhibitors. All subjects had regression of their CNV lesions after VEGF
blockade. Two subjects developed foveal atrophy.
Conclusions: This case series depicts the changes on FA seen over a 4-year period and shows
that GA can occur with regression of CNV after treatment with VEGF inhibitors.

Introduction

Assoc. Prof. Diana V. Do, MD

The Wilmer Eye Institute
600 North Wolfe Street, Maumenee 745
Baltimore, MD 21287 (USA)
Tel. +1 410 502 0766, E-Mail ddo @ jhmi.edu

Downloaded by:
University of Nebraska - Med.Center
137.197.85.77 - 9/23/2014 10:14:55 PM

Intravitreal vascular endothelial growth factor (VEGF) inhibitors are the standard
treatment for subfoveal choroidal neovascularization (CNV) due to age-related macular
degeneration (AMD) [1, 2]. Though the original dosing regimen studied involved
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monthly injections, recently it has been observed that monthly follow-up with as
needed treatment decreased the number of injections without sacrificing the gain in
visual acuity [3–5]. Currently, most retina specialists employ optical coherence
tomography (OCT) to evaluate CNV lesions and determine if additional VEGF inhibition
is needed. Although OCT has become the mainstay for retinal imaging, fluorescein
angiography (FA) is still important in the diagnosis and monitoring of retinal
pathologies such as CNV, especially when geographic atrophy (GA) develops after CNV
regression [6, 7].
We conducted a retrospective study to evaluate the dynamic changes seen on FA in 3
patients who had undergone serial FA imaging over 48 months of treatment with
intravitreal (IVT) VEGF inhibitors for neovascular AMD.

Materials and Methods
This study was approved by the Johns Hopkins Institutional Review Board, which granted a waiver
of consent for access to medical records for all persons included in the study. Retrospective chart
review was performed for patients who had routine fluorescein angiograms and OCT performed as
they were being treated with intravitreal VEGF inhibitors for neovascular AMD. Three sample cases
are described below.

Case Reports
Case 1
Patient 1 is a 75-year-old man who presented with decreased vision. Initially, his visual acuity was
found to be 20/ 63 in the left eye with subfoveal CNV due to AMD. Baseline FA revealed a small
subretinal hemorrhage and leakage from classic CNV (fig. 1a). One month after receiving an IVT
injection with ranibizumab (RBZ), the CNV lesion decreased in size (fig. 1b), and it continued to
regress and show decreasing amounts of leakage at months 3 and 6, stabilized at month 9, and
increased in leakage at month 12 (fig. 1c–f) as the patient received additional RBZ on an as needed
basis depending on CNV activity seen on either FA and/or OCT. At month 47 and after a total of 16
ranibizumab injections, the CNV had completely regressed. However, GA had developed over the
fovea resulting in a visual acuity (VA) of 20/250 (fig. 1g).
Case 2
Patient 2 is an 85-year-old man who presented with a VA of 20/80 in his right eye and subfoveal
occult CNV due to AMD. On presentation, the CNV lesion was greater than 9 disc areas. One month
after treatment with ranibizumab, the CNV had regressed and there was decreased leakage on FA.
There was continued CNV regression through months 3, 6, 9 and 12 as the patient received additional
RBZ on an as needed basis. At month 48 and after a total of 23 RBZ injections, there was no CNV
leakage remaining, and the VA was 20/50, but some extrafoveal GA had developed.
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Case 3
Patient 3 is an 80-year-old woman who presented with a VA of 20/125 and subfoveal occult CNV
due to AMD in the left eye. At the initial visit, there was subretinal hemorrhage and leakage from CNV
(fig. 2a). After 2 RBZ treatments, there was regression of the CNV lesion at month 2 (fig. 2b), but
leakage returned through month 12 (fig. 2c–e). This patient was followed up for a total of 57 months,
during which she received 20 RBZ injections and 2 bevacizumab injections. At her most recent visit,
there was foveal GA with no CNV leakage, and her VA was 20/125 (fig. 2f).
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Discussion
Both FA and OCT images are able to monitor CNV activity after VEGF inhibition [8].
However, despite OCT being more commonly used today to monitor CNV lesions, FA
and OCT have different benefits and limitations. OCT allows for visualization of the
retina to document intraretinal or subretinal fluid and elevation of the retinal pigment
epithelium (RPE) associated with CNV. FA visualizes the actual extent and size of the
CNV lesion and documents leakage associated with it. Although spectral domain- (SD)
OCT can sample a large area of the retina with high resolution, it still cannot document
the extent of CNV seen on FA [9]. FA can truly document both the size of the CNV lesion
and regression of it after treatment with VEGF inhibition, and aid in the diagnosis of
geographic atrophy. More recently, ophthalmologists have also been employing SD-OCT
for identifying areas of geographic atrophy that could be responsible for poor visual
outcomes after anti-VEGF therapy.
Few studies have described long-term changes in CNV lesions with FA after VEGF
inhibition. This case series documents CNV regression induced by anti-VEGF therapy. In
addition, it documents the development of atrophy in the macula after CNV regression.
The GA may be due to the natural history of the disease or it may be accelerated by CNV
regression by anti-VEGF therapy. Rosenfeld et al. [10] evaluated causes of vision loss
after anti-VEGF therapy and also demonstrated that RPE changes and atrophy were
common causes of vision loss after long-term use of RBZ for neovascular AMD. Their
study evaluated 71 eyes that lost at least 15 letters of VA over a 24-month period, and
they found that RPE atrophy and/or abnormalities were the most common causes of
visual loss among these patients. Additional studies of OCT and FA would be helpful to
identify if chronic anti-VEGF therapy increases the risk of GA. In addition to OCT, FA is
still an important tool for monitoring CNV activity after VEGF inhibition and for
documenting CNV regression and the development of atrophy in the macula.
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Fig. 1. Late-phase fluorescein angiograms from a patient treated with ranibizumab on an as needed
basis over 47 months. The CNV lesion measured 2 disc areas at baseline (a). After the initial
ranibizumab treatment, the CNV lesion decreased in size at month 1 (b) month 3 (c) and month 6 (d),
maintained this size through month 9 (e), and increased at month 12 (f). At 47 months (g), there was
no CNV activity but geographic atrophy had developed.
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Fig. 2. Late-phase fluorescein angiograms from a patient treated with bevacizumab at baseline and
treated with either bevacizumab or ranibizumab on an as needed basis for 57 months. The CNV
lesion measured 1–2 disc areas at baseline (a). The lesion decreased in size slightly at month 1 (b)
and then leaked more at month 5 (c), month 9 (d) and month 12 (e). Over 57 months, the CNV
activity completely regressed though geographic atrophy had developed (f).
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